265 related articles for article (PubMed ID: 10894820)
1. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
[TBL] [Abstract][Full Text] [Related]
2. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
[TBL] [Abstract][Full Text] [Related]
3. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis.
Huang Y; Ji ZS; Brecht WJ; Rall SC; Taylor JM; Mahley RW
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2952-9. PubMed ID: 10591675
[TBL] [Abstract][Full Text] [Related]
5. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
[TBL] [Abstract][Full Text] [Related]
6. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice.
Tsukamoto K; Maugeais C; Glick JM; Rader DJ
J Lipid Res; 2000 Feb; 41(2):253-9. PubMed ID: 10681409
[TBL] [Abstract][Full Text] [Related]
7. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
9. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia.
Huang Y; Liu XQ; Rall SC; Taylor JM; von Eckardstein A; Assmann G; Mahley RW
J Biol Chem; 1998 Oct; 273(41):26388-93. PubMed ID: 9756870
[TBL] [Abstract][Full Text] [Related]
10. Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase.
de Man FH; de Beer F; van de Laarse A; Smelt AH; Leuven JA; Havekes LM
Atherosclerosis; 1998 Feb; 136(2):255-62. PubMed ID: 9543096
[TBL] [Abstract][Full Text] [Related]
11. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
[TBL] [Abstract][Full Text] [Related]
12. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice.
Kypreos KE; Morani P; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2001 May; 40(20):6027-35. PubMed ID: 11352738
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
Huang Y; Liu XQ; Rall SC; Mahley RW
J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production.
Post SM; Groenendijk M; Solaas K; Rensen PC; Princen HM
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):768-74. PubMed ID: 14962946
[TBL] [Abstract][Full Text] [Related]
15. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
Gerritsen G; Kypreos KE; van der Zee A; Teusink B; Zannis VI; Havekes LM; van Dijk KW
J Lipid Res; 2003 Feb; 44(2):408-14. PubMed ID: 12576523
[TBL] [Abstract][Full Text] [Related]
16. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1.
Jong MC; Dahlmans VE; van Gorp PJ; Breuer ML; Mol MJ; van der Zee A; Frants RR; Hofker MH; Havekes LM
Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):934-40. PubMed ID: 8696956
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides.
Hara M; Iso-O N; Satoh H; Noto H; Togo M; Ishibashi S; Kimura S; Kadowaki T; Hashimoto Y; Tsukamoto K
Metabolism; 2006 Aug; 55(8):1129-34. PubMed ID: 16839851
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
Mensenkamp AR; Jong MC; van Goor H; van Luyn MJ; Bloks V; Havinga R; Voshol PJ; Hofker MH; van Dijk KW; Havekes LM; Kuipers F
J Biol Chem; 1999 Dec; 274(50):35711-8. PubMed ID: 10585451
[TBL] [Abstract][Full Text] [Related]
19. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
20. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
